FDA says Jiangsu Shenli marketed many piston syringes in the U.S. without required clearance or approval.
What happened
FDA says it learned from the firm’s information and FDA public databases that Jiangsu Shenli was marketing piston syringes in the United States; the letter does not describe an inspection. FDA found the firm had cleared only a 5cc luer lock syringe but was distributing other sizes, luer slip tips, colored syringes, drug-specific syringes, and control syringes without a new 510(k) or approval. FDA also cited multiple customer complaints of cracks and breakage during use in surgical kits.
What FDA found
The firm marketed piston syringes without an approved premarket approval application or investigational device exemption, so FDA considers them adulterated.
section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)The firm changed the cleared 5cc luer lock syringe by adding other sizes, luer slip tips, drug-specific labels, colors, and control syringes without submitting a new 510(k).
section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)(3)(i)-(ii)FDA says these design changes could cause patient harm such as inaccurate dosing, leaks, inappropriate needle detachment, and incorrect device handling.
FDA says added color additives could cause adverse health effects including allergic reactions, irritation, pain, fever, red blood cell damage, and organ toxicity.
FDA says labeling syringes for specific drugs can cause harm because drug viscosity differences can lead to inaccurate dosing or incorrect drug use.
What FDA wants
FDA asks the firm to stop activities that cause misbranding or adulteration, including U.S. commercial distribution to importers, distributors, or other third parties. The firm must reply in writing within 15 business days with corrections, corrective actions, and a timetable if work will continue past that time.
Who should pay attention
- U.S. importers and distributors of piston syringes
- surgical kit assemblers and hospital supply buyers
- companies sourcing colored or drug-specific syringes from this maker
This is a summary. Read the original letter on fda.gov.